CD19 and metabolic syndrome: Through a case-control study involving 140 participants and an animal experiment, we identified significantly elevated counts of peripheral blood CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD19+ B cells in patients with dyslipidemia, alongside increased specific bile acids in fecal samples and distinct alterations in gut microbiota composition.